|
Dr. Karen K. Oishi has led the successful transfer of CTT to Chlorogen from its inventors, Dr. Henry Daniell and Dr. Pal Maliga, of the University of Central Florida and Rutgers University. She and her team of scientists will now leverage the many advantages of CTT to develop Chlorogen's first commercial product and expand the product pipeline. Dr. Oishi has extensive experience in producing and purifying complex human therapeutic proteins in tobacco plants and has done extensive research with chloroplasts and chloroplast transformation. Most recently, as Chief Scientist and Senior Vice President for CropTech Corporation, she raised several million dollars in federal grants to conduct research and to develop plant-made treatments for a number of conditions, including cancer, HIV and Hurler syndrome. Dr. Oishi received her Ph.D. in biological sciences in 1983 from the University of California - Irvine, where she did her dissertation and experimental research with chloroplast DNA. She was an NSF Post-Doctoral Fellow at the University of California - Berkeley, where she worked on chloroplast transformation. From 1987 to 1994, she was an Assistant Professor at the University of Arizona in the Department of Molecular and Cellular Biology and the Department of Plant Sciences. Dr. Oishi's work has been published in more than 25 peer-reviewed publications, and she has received one patent and has applied for two others during the course of her research. | 